Why Most Women Who Could Benefit from HRT Still Are Not Taking It

Two decades after the Women's Health Initiative scared a generation off hormone therapy, the evidence has swung back toward benefit for many women. Yet a 2026 Mayo Clinic analysis shows use kept falling, from 4.4 percent in 2007 to 1.7 percent in 2023, even among those most likely to benefit.

Key Takeaways

• Hormone therapy use dropped from 4.4 percent in 2007 to 1.7 percent in 2023 despite updated evidence of benefit (Mayo Clinic, June 2026).
• The "timing hypothesis" shows the best risk-benefit for women starting therapy near menopause, typically under 60 or within 10 years.
• Residual fear from the 2002 WHI headlines, not new data, drives much of the avoidance.
• Transdermal estrogen and micronized progesterone carry better safety profiles than the old oral conjugated equine estrogen plus progestin regimen.

What Did the 2026 Analysis Find?

Mayo Clinic researchers reported that hormone therapy use declined steadily even as reanalysis of older studies and newer data supported benefits for symptom relief and possible cardiovascular and bone protection when started early (Mayo Clinic News Network, June 2026). The drop was sharpest among women who stood to gain the most: those in early menopause.

This widens the conversation beyond our HRT black-box removal guide and the estrogen risk-benefit piece. The science moved, but prescribing did not follow.

Citation capsule: A Mayo Clinic study published in 2026 found menopausal hormone therapy use fell from 4.4 percent in 2007 to 1.7 percent in 2023, a decline that persisted even as two decades of reanalysis reframed the risk-benefit picture in favor of early, appropriate use (Mayo Clinic, 2026).

Why Does Timing Matter So Much?

The "timing hypothesis" is the key. Women who start hormone therapy close to menopause, generally under 60 or within 10 years of onset, show better cardiovascular and overall profiles than those who start late (cardiometabolic trials, 2022 to 2025). The WHI, which fueled the fear, studied women whose average age was 63, well past that window.

That distinction reframes the whole debate. Early, physiologic-dose therapy is a different risk proposition than late, high-dose treatment. Our perimenopause cardiovascular risk guide covers why midlife cardiovascular strategy matters.

What Changed in the Evidence?

Beyond timing, formulation matters. Transdermal estrogen (patches, gels) bypasses the liver and avoids the clot-risk bump tied to oral estrogen, and micronized progesterone is preferred over older synthetic progestins (menopause society guidance, 2025 to 2026). The 2026 FDA label changes removed outdated boxed warnings, as our black-box removal guide details.

For non-hormonal options, our Veozah hot-flash guide covers a different path for those who decline hormones.

Why Are Women Still Avoiding It?

Mostly lingering fear. The 2002 headlines were louder than the corrections. Many clinicians also still under-prescribe, unsure of the updated framing. The result is millions of women enduring hot flashes, sleep loss, and mood disruption that therapy could ease.

Our perimenopause brain fog guide and 3 a.m. waking guide show how disruptive untreated symptoms are, which raises the cost of avoidance.

Frequently Asked Questions

Is HRT safe in 2026?

For most healthy women near menopause, the benefits outweigh risks, especially with transdermal estrogen and micronized progesterone.

Why did use keep dropping?

Residual fear from the 2002 WHI study and cautious prescribing outlasted the corrected evidence (Mayo, 2026).

Who should avoid HRT?

Those with a history of estrogen-sensitive cancer, untreated hypertension, or clotting disorders need individualized assessment.

Does it help with more than hot flashes?

Yes. Evidence supports bone, mood, and sleep benefits when started in the window, though individual results vary.

Conclusion

The 2026 data show hormone therapy use kept falling even as the evidence improved, a gap driven by old fears more than new facts. For women near menopause, modern low-dose, transdermal regimens offer relief with a better safety profile than the regimen that sparked the panic. Talk to a menopause-informed clinician about whether you are a candidate.

Cluster: This article belongs to our women's health and menopause cluster. Read HRT black-box removed, estrogen risk-benefit, perimenopause cardiovascular risk, and Veozah for hot flashes.